Breast Cancer Therapeutics Market Expands in Asia-Pacific, According to a New Study on ASDReports

 
ASDReports.com
ASDReports.com
AMSTERDAM, Netherlands - June 27, 2014 - PRLog -- Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%, forecasts the new report.

According to the new report, now available on ASDReports, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.

Saurabh Sharma, Analyst of the new report, says: “The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab.”

These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer’s palbociclib and neratinib, and Boehringer Ingelheim’s afatinib, will also contribute.

Sharma continues: “The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies.”

From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to the new study now available on ASDReports!


Notes for Editors:

If you are interested in a more detailed overview of this report, please go to : www.asdreports.com/ASDR-109564 or send an e-mail to sales@asdreports.com.

Media Contact
ASDReports.com
+31 (0)20 486 9620
stefan.koopman@asdreports.com

Photo:
http://www.prlog.org/12341029/1
End
Source:ASDReports.com
Email:***@asdreports.com Email Verified
Tags:Breast Cancer, Life Sciences, Diseases, Market Research, Market Report, ASDReports
Industry:Marketing, Reports, Research
Location:Amsterdam - Amsterdam - Netherlands
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share